GenVec, Inc. company was founded in 1992 and is based in Gaithersburg, Maryland. GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic, wfor the treatment of various cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, it is developing TherAtoh, a preclinical program involving the delivery of the human atonal gene for the production of therapeutic proteins by cells in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and HSV-2. It has strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATH'S malaria vaccine initiative, the U.S. naval medical research center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

ALK is a global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. We are devoted to improving quality of life for people with allergies by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction.

GlaxoSmithKline Pharmaceuticals (GSK India) is the top of the pill heap. India's leading pharmaceutical manufacturer, the company makes pharmaceuticals and consumer health care products through its two manufacturing facilities in Nashik and Thane; it also has a clinical development center in Bangalore. Its products include those targeting problems with infections, gynecology, dermatology, diabetes, and the cardiovascular system. Top sellers are Augmentin, Zinetac, Calpol, Phexin, and Betnesol. GSK India also makes vaccines to treat or prevent hepatitis A and B, the flu, chickenpox, and tetanus. Its distribution network stretches throughout the country. UK-based drugmaker GlaxoSmithKline owns GSK India.

CombiMatrix Corporation company was founded in 1995 and is based in Mukilteo, Washington. CombiMatrix Corporation, together with its subsidiaries, develops technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, defense, and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology.CombiMatrix Corporation's products and services include CustomArray platform, an oligonucleotide array for genetic studies; CatalogArray Microarrays for gene expression studies, mutation analysis, and other studies; Micro-RNA Arrays that are used to study micro-RNA molecules; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. CombiMatrix Corporation also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, the company develops capabilities of producing arrays that utilize bacterial artificial chromosomes that enable genetic analysis; and a series of compounds to address various oncology-related diseases. It sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia.

Laboratoires Arkopharma's products offer a glimpse of modern worries: ampoules of fat reducers, tablets to help quit smoking, creams to tackle cellulite, and capsules to alleviate anxiety and stress. Arkopharma produces plant-derived OTC drugs and nutritional supplements. The company also manufactures homeopathic remedies and cosmetics. Arkopharma markets its products under a variety of brands, including Arkocaps, Arkofluide, 4.3.2.1. Slim, Phyto Soya, and Plante System. Subsidiaries of the company can be found in Australia, Europe, and the UK. The founding Rombi family controls the company through its holding company Imarko.

MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California. MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. MAPP company's product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

Inhibitex, Inc. was founded in 1994 and is based in Alpharetta, Georgia. Inhibitex, Inc., a biopharmaceutical company, develops differentiated anti-infective products to prevent and treat serious infections primarily shingles and chronic hepatitis C. Its anti- infective product candidates include FV-100, an orally available nucleoside analogue prodrug, which completed Phase I trials used for the treatment of herpes zoster or shingles; and aurexis, a humanized monoclonal antibody, which completed Phase IIa trials used for the treatment of serious S. aureus infections. The company's preclinical product candidates include HCV polymerase inhibitors, which are used for the treatment of chronic HCV infection; HIV integrase inhibitors that are used for the treatment of HIV infection; and staphylococcal vaccines, an active vaccine to prevent S. aureus infections. It has MSCRAMM based license and collaboration agreement with Wyeth Pharmaceuticals for the development of staphylococcal vaccines; and royalty-bearing license agreement with Cardiff University and Katholieke Universiteit for intellectual property of HCV nucleoside polymerase inhibitors.

AlphaVax, Inc. company was founded in 1998 by Robert Johnston, Nancy Davis, and Jonathan Smith, AlphaVax's chief scientific officer. AlphaVax, Inc. company is developing new vaccines for cancers and infectious diseases such as HIV/AIDS, Ebola, influenza, and other viral maladies. AlphaVax relies on a proprietary alphavaccine system that genetically alters diseased cells and transforms them into a vaccine when they attempt to replicate. Its technology could be used to develop preventative vaccines and therapeutic vaccines. Its pipeline consists of early-stage candidates. AlphaVax receives funding through partnerships and grants.

Nanospectra Biosciences, Inc. was founded in 2002 and is based in Houston, Texas. Nanospectra Biosciences, Inc., a medical device company, engages in developing and commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors. The company provides AuroLase Therapy, a medical device that is applicable to the ablation of various solid tumors. It also offers research-use-only nanoparticles with specific optical characteristics.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.